Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study

食管切除术 医学 佐剂 肿瘤科 免疫疗法 食管鳞状细胞癌 新辅助治疗 内科学 基底细胞 癌 食管癌 普通外科 癌症 乳腺癌
作者
Jifeng Feng,Liang Wang,Xun Yang,Qixun Chen
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:15: 1456193-1456193 被引量:6
标识
DOI:10.3389/fimmu.2024.1456193
摘要

Background The role of immunotherapy in the adjuvant setting seems promising in recent years. As per the findings of the CheckMate 577 trial, patients with esophageal cancer (EC) who had neoadjuvant chemoradiation with residual pathologic disease should be considered adjuvant immunotherapy (AIT). However, it is unknown if individuals with esophageal squamous cell carcinoma (ESCC) who have received neoadjuvant immunochemotherapy (NICT) followed by radical surgery also require AIT. Methods A retrospective analysis was performed on the data from patients who underwent NICT and radical surgery for ESCC between 2019 and 2020. To compare disease-free survival (DFS) and overall survival (OS), Kaplan-Meier survival curves were produced. To determine the parameters linked to DFS and OS, a Cox model using hazard ratios (HRs) was completed. Results Among the 292 eligible patients, 215 cases with a mean age of 63.3 ± 6.8 years, including 190 (88.4%) men and 25 (11.6%) women, were finally recruited. The percentage of R0 resection was 98.3%. After NICT, 65 (30.2%) patients achieved pathological complete response. AIT was given to 78 (36.3%) patients following radical resection. For all patients, the 3-year DFS and OS were 62.3% and 74.0%, respectively. In terms of 3-year DFS (61.5% vs. 62.8%, P=0.984) or OS (76.9% vs. 72.3%, P=0.384), no statistically significant difference was found between patients with and without AIT. AIT significantly improved survival in patients with ypT+N+ (DFS: 23.9% vs. 38.5%, P=0.036; OS: 37.0% vs. 61.5%, P=0.010), but not in those with ypT0N0 or ypT+N0. It was found that AIT was related to both DFS (HR: 0.297; P<0.001) and OS (HR: 0.321; P=0.001) in patients with ypT+N+. Conclusion In ypT+N+ ESCC patients, AIT after NICT followed by radical surgery reduces the recurrence and death, thereby improving the DFS and OS. Randomized controlled trials ought to be conducted to further assess the results of this retrospective investigation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
邓梅发布了新的文献求助10
刚刚
8888完成签到,获得积分10
刚刚
自然幻竹发布了新的文献求助10
1秒前
1秒前
自信萃完成签到 ,获得积分10
1秒前
1秒前
Yearning完成签到,获得积分10
2秒前
苹果大王完成签到 ,获得积分10
2秒前
草东树发布了新的文献求助10
3秒前
3秒前
Jasper的应助被科研菜鸟望毕业采纳,获得10
3秒前
才染发布了新的文献求助10
3秒前
3秒前
5秒前
花紫晴完成签到 ,获得积分10
5秒前
6秒前
忧虑的盼山完成签到,获得积分10
6秒前
7秒前
7秒前
Owen的应助被寄晴采纳,获得10
7秒前
cijing发布了新的文献求助10
7秒前
8秒前
ATX完成签到,获得积分10
8秒前
张三发布了新的文献求助10
8秒前
吹泡泡的红豆完成签到,获得积分10
9秒前
9秒前
顾昀发布了新的文献求助10
9秒前
英姑的应助被拔丝香芋采纳,获得10
10秒前
11秒前
Victory发布了新的文献求助10
11秒前
orixero的应助被sunny111采纳,获得10
12秒前
闪闪松鼠发布了新的文献求助10
12秒前
李健的应助被slgzhangtao采纳,获得10
12秒前
12秒前
12秒前
李健的应助被搞怪画笔采纳,获得10
13秒前
F衣衫褴褛完成签到,获得积分10
14秒前
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 1000
Электротехническая система магнитожидкостной герметизации валов регулируемых электродвигателей 800
Guidelines for fracture-safe and fatigue-reliable design of steel structures 600
The Basics of Practical Optimization, Second Edition 600
Problems and Solutions for Integer and Combinatorial Optimization: Building Skills in Discrete Optimization 600
Organizational Behavior 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 7984885
求助须知:如何正确求助?哪些是违规求助? 9444390
关于积分的说明 21090880
捐赠科研通 7559412
什么是DOI,文献DOI怎么找? 3376953
关于科研通互助平台的介绍 2510911
邀请新用户注册赠送积分活动 2410220